Academic Commercialisation: The Third Way?

In an earlier post, Fail Fast Fail Early, focused on healthcare companies optimising their pipeline development, I asked whether there was a better way of commercialising medicines. Well GSK and Cambridge University have come with an interesting alternative development model using “academic incubators” to optimise the early clinical development of new medicines.

Cambridge will dedicate a team of academic experts to develop drugs with therapeutic potential, as well as bearing some financial risk for which they'd be compensated if the programme is a success. GSK will provide operational support, access to its in-house clinical research and imaging facilities, and background preclinical data on the drug. The agreement is fully aligned with one of the key recommendations of the Cooksey Review of UK Health Research Funding that consideration should be given to alternative drug development models, such as Public Private Partnerships, to optimise effective collaboration between industry and academic sectors in the development of effective new medicines.

Whether this is "ground-breaking approach" or just a sensible way of outsourcing development of low priority orphan drugs is open to debate. It does however establish a joined up pipeline from academic research towards commercialisation that may university inspired projects lack - despite their efforts to bolt on commercialisation activities. Also the fact that the projects are GSK sponsored gives a commercial focus to the activity from the outset that will undoubtedly benefit the eventual business outcomes. As we have seen with the Enterprise Fellowship projects backed by Yorkshire Forward, having some commercialisation DNA and focus at an early stage is invaluable.

Making Your Own Luck

Gary Player once remarked "It's funny, the more I practise, the luckier I get". So should a failed entrepreneur be given a second chance? The argument goes that you learn valuable learn valuable lessons from failure, so you should be more likely to succeed second time around. But others argue that experience gained from one failed business is unlikely to apply to a second, due to the unpredictability of chance. "You can't learn to win the lottery" No, but if you are lucky you can influence the amount you win (my tip, don't select the numbers 1,2,3,4,5,6 as 10,000 others have then!).

Getting into a position to profit from being a little bit lucky is probably was differentiates successful entrepreneurs, but no one is lucky all of the time. So whether you eventually profit from a bit of good business fortune is very much down to the experience of the management team. All you can do is deal yourself a good hand, but whether you win a particular pot or hole a specific putt is partially down to fate. Embracing this risk is what equity investing is all about. So if anyone says they have only been associated with success they have either are a one-trick pony or very, very lucky! In business, lessons are best learned from those who have been mainly successful...